Early Intervention to Prevent Development of PTSD in Burn Survivors and Their Caregivers
14 juni 2026 uppdaterad av: University of Southern California
The purpose of this clinical trial is to adapt and test a brief patient-caregiver early intervention designed to reduce posttraumatic stress symptoms in hospitalized burn patients and their caregivers.
This intervention is a brief, 4-session cognitive-behavioral intervention designed for burn patients and their loved one to complete together, during and after hospitalization.
The intervention targets relational communication and functioning through reduction of invalidating, negative statements and avoidant coping by teaching patients and their loved ones to engage in adaptive natural disclosures, supportive responses, and approach coping after the burn trauma.
The intervention uses evidence-based psychotherapy techniques, including psychoeducation, motivational interviewing, and skills coaching.
The clinical trial will occur in two sequential phases.
In the first phase of the study (case series), the intervention will be provided to two burn patient-caregiver dyads (four adults) to pilot test the intervention, seek patient and provider feedback, and refine the intervention.
All four adults will receive the intervention.
In the second phase of the study, the randomized controlled trial (RCT) phase, investigators will enroll 20 more burn patient-caregiver dyads (40 more adults) who will be randomly assigned (like the flip of a coin) at the dyad level to receive the intervention or a burn survivor-only minimally enhanced usual care psychoeducation control condition (mEUC).
The goals of the RCT phase are to study whether the intervention is acceptable to patients, feasible to conduct, and whether the intervention improves burn survivor-caregiver healthy relationship communication about difficult events and treatment outcomes compared to mEUC.
Studieöversikt
Status
Har inte rekryterat ännu
Betingelser
Studietyp
Interventionell
Inskrivning (Beräknad)
44
Fas
- Inte tillämpbar
Kontakter och platser
Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.
Studiekontakt
- Namn: Sarah Stoycos, PhD
- Telefonnummer: 323-409-7621
- E-post: sarah.stoycos@med.usc.edu
Studieorter
-
-
California
-
Los Angeles, California, Förenta staterna, 90033
- University of Southern California, Keck School of Medicine & Los Angeles General Medical Center
-
Kontakt:
- Sarah Stoycos, PhD
- Telefonnummer: 323-409-7621
- E-post: sarah.stoycos@med.usc.edu
-
-
Deltagandekriterier
Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.
Urvalskriterier
Åldrar som är berättigade till studier
- Vuxen
- Äldre vuxen
Tar emot friska volontärer
Ja
Beskrivning
Inclusion Criteria:
- Alert, oriented, & not withdrawing from substance at time of screening
- Can read and write in English
- Hospitalized within 10 days of burn injury
- Anticipated discharge <=4 weeks
- Have an email, mailing address, and at least 1 smart device for telehealth sessions
- PTSD risk score of 2 or greater (patient-only)
- Willing to attend therapy sessions with a loved one
Exclusion Criteria:
- Currently incarcerated or in police custody
- > 10 days post-burn
- Lifetime diagnosis of primary psychosis or intellectual disability
- Ongoing reported domestic violence in the dyad
- Unstable bipolar disorder, severe substance use disorder, or acute suicidality with imminent intent that does not remit within 10 days of burn-injury
- Inflammation Confounds (patient-only) of BMI > 40, metabolic syndrome, admission A1C of >= 6.5%
- Currently receiving couples therapy
Studieplan
Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Förebyggande
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Enda
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Promotion of Emotional Disclosure for Burns (PoED-B)
Participants randomized into this arm will receive Promotion of Emotional Disclosure for Burns (PoED-B), a cognitive behavioral therapy intervention designed for burn survivors and a loved one of their choosing to complete together.
The standard treatment length will be 4 sessions, however participants and providers may agree to additional sessions as warranted.
|
PoED-B is a dyadic treatment where both patient and identified informal caregiver participate.
PoED-B targets reducing disclosure-constraining behaviors (e.g., invalidating, negative statements) using psychoeducation, motivational interviewing, and skills training.
The goal is to encourage the patient-caregiver dyad to engage in natural disclosures, supportive responses, and approach coping after the burn trauma to facilitate emotional processing.
It is four sessions long.
Delivery format takes into account stakeholder feedback, considering overall burden during acute hospitalization and the transition to outpatient care.
Sessions one and two are 30 minutes and one week apart.
Sessions three and four are 50 minutes long and two weeks apart.
Session one must occur during hospitalization.
Sessions 2-4 can be completed via video/telehealth if the patient is discharged during the treatment course.
|
|
Aktiv komparator: minimally Enhanced Usual Care control (mEUC)
Participants randomized into this arm will receive a minimally enhanced version of usual burn care.
This will include one, 30-minute supportive therapy session focused on psychoeducation about the potential psychological impact of burn injury and hospitalization and referral to outpatient resources, if wanted.
|
mEUC is an individually-administered psychoeducation control for burn patients modeled after minimally enhanced care in acute care surgery units.
In one 30-minute session, the therapist reviews with the participant a standardized psychoeducation handout on common psychological reactions after burn injury, giving them time to ask questions or express concerns within a supportive therapy framework.
Then, the participant is given the handout, which also includes self-help skills.
After study completion, participants will be given referrals for outpatient mental health services.
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Social Constraints Scale
Tidsram: Before treatment, immediately after ending treatment, 6-week follow-up
|
The Social Constraints Scale is a self-report scale administered to both the patient and caregiver.
It is designed to assess perceptions of negative reactions to trauma-disclosures.
The scale contains 15 items, and each item is scored on a four-point scale ranging from 1 (never) to 4 (often) with total scores ranging from 15 to 60.
A higher score indicates a higher frequency of experiencing social constraints.
|
Before treatment, immediately after ending treatment, 6-week follow-up
|
|
Feasibility of Recruitment
Tidsram: baseline
|
Proportion of participants who agree to participate from the total number of those that are eligible and approached.
|
baseline
|
|
Feasibility of Data Collection
Tidsram: From enrollment to the end of study assessments at 6-weeks posttreament
|
Proportion of participants who completed each and all assessment timepoints
|
From enrollment to the end of study assessments at 6-weeks posttreament
|
|
Acceptability: Satisfaction with Treatment
Tidsram: Immediately after ending treatment
|
Client Satisfaction Questionnaire (CSQ) - Self-Report - The CSQ has 8 items assessing client satisfaction with the treatment they have received.
Total scores range from 8-32; higher scores indicate greater client satisfaction/treatment acceptability.
This measure will be completed by both patients and their loved ones.
|
Immediately after ending treatment
|
|
Acceptabilitly: Retention
Tidsram: Immediately after ending treatment
|
Proportion of enrolled dyads who completed at least 3 out of 4 PoED sessions.
|
Immediately after ending treatment
|
|
Acceptability: Global Improvement Rating
Tidsram: Immediately after ending treatment
|
Proportion of participants who report overall improvement on the Global Rating of Change Scale
|
Immediately after ending treatment
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
PTSD Checklist for DSM-5 (PCL-5)
Tidsram: Pretreatment, Immediately after ending treatment, 6-week follow-up
|
The PTSD Checklist for DSM-5 is a 20 item self-report measure assessing PTSD symptom severity.
Total scores range from 0-80 with higher scores indicating more severe PTSD symptoms.
|
Pretreatment, Immediately after ending treatment, 6-week follow-up
|
|
Clinician-Administered PTSD Scale for DSM-5 (CAPS-5)
Tidsram: Immediately after ending treatment, 6-week follow-up
|
The Clinician-Administered PTSD Scale for DSM-5 is a structured interview measure of PTSD symptom severity (frequency and intensity) in the past month.
Scores can range from 0-80, with higher scores indicating worse symptom severity.
Only burn patients will complete this measure, not caregivers.
|
Immediately after ending treatment, 6-week follow-up
|
|
Hospital Anxiety and Depression Scale (HADS)
Tidsram: Pretreatment, immediately after ending treatment, 6-week follow-up
|
The Hospital Anxiety and Depression Scale is a 14-item self-report measure of anxiety and depression symptoms that was designed for the hospital environment.
Each subscale has 7-items answered on a 4-point scale ranging from 0 to 3, yielding a maximum possible score of 21 for each subscale.
Higher scores indicate worse symptoms.
|
Pretreatment, immediately after ending treatment, 6-week follow-up
|
|
MINI Montreal International Neuropsychiatric Interview v. 7.0.2 (MINI)
Tidsram: Pretreatment, immediately after ending treatment, 6-week follow-up
|
The MINI is a brief (~15 minutes) structured psychodiagnostic interview for assessing DSM-5 disorders.
|
Pretreatment, immediately after ending treatment, 6-week follow-up
|
|
Dyadic Relationship Scale (DRS)
Tidsram: Pretreatment, immediately after ending treatment, 6-week follow-up
|
The Dyadic Relationship Scale is a self-report survey measuring dyadic strain and positive dyadic interaction specific to patient's health.
There is a 10-item patient-version and 11-item caregiver version.
Dyadic strain subscale scores range from 0-12 (patient version) and 0-15 (caregiver version).
Positive dyadic interaction subscale scores range from 0-18.
Higher scores on each of these scales indicate higher levels of strain and positive interaction, respectively.
|
Pretreatment, immediately after ending treatment, 6-week follow-up
|
|
Significant Other's Responses to Trauma Scale (SORTS)
Tidsram: Pretreatment, immediately after ending treatment, 6-week follow-up
|
The Significant Other's Responses to Trauma Scale is a 14-item self-report measure assessing frequency & intensity of caregiver PTSD accommodation behaviors.
Total scores can range from 0-112 with higher scores indicating greater accommodation.
|
Pretreatment, immediately after ending treatment, 6-week follow-up
|
Samarbetspartners och utredare
Det är här du hittar personer och organisationer som är involverade i denna studie.
Utredare
- Huvudutredare: Sarah Stoycos, PhD, University of Southern California, Keck School of Medicine
Studieavstämningsdatum
Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.
Studera stora datum
Studiestart (Beräknad)
1 augusti 2026
Primärt slutförande (Beräknad)
31 december 2028
Avslutad studie (Beräknad)
28 februari 2029
Studieregistreringsdatum
Först inskickad
3 juni 2026
Först inskickad som uppfyllde QC-kriterierna
14 juni 2026
Första postat (Faktisk)
18 juni 2026
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
18 juni 2026
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
14 juni 2026
Senast verifierad
1 juni 2026
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- HS-25-00383
- 1K23MH141296-01 (U.S.S. NIH-anslag/kontrakt)
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
JA
IPD-planbeskrivning
De-identified demographic and raw quantitative data will be deposited into the NIMH Data Archive (NDA).
All data will be de-identified prior to receipt by the repository.
Data will be de-identified pursuant to the HIPAA Privacy Rule, 45 CFR § 164.514(b).
A brief study protocol will also be submitted to NDA and will be made freely available.
Tidsram för IPD-delning
Data will be deposited starting 18 months after the award begins and will be deposited every six months thereafter following the usual NDA data submission dates.
Data generated from this project will be made available as soon as possible, and no later than the time of publication or the end of the funding period, whichever comes first.
The duration of preservation and sharing of the data is controlled by the NDA; NDA currently has no process for deleting or retiring datasets, and thus far no data has been removed to our knowledge.
Kriterier för IPD Sharing Access
To request access to the data, researchers can use the standard processes at NDA; the NDA Data Access Committee will review requests and decide which requests to grant.
The standard NDA access process allows access for one year and is renewable thereafter.
IPD-delning som stöder informationstyp
- STUDY_PROTOCOL
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Nej
Studerar en amerikansk FDA-reglerad produktprodukt
Nej
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .